The maintained selection of key pathways over disease-course (eg, SHH/WNT/P53 pathways) supports their relevance at both diagnosis and relapse, and the utility of molecular diagnostics of the tumor at diagnosis to stratify associated targeted therapies (eg, SMO inhibitors for SHH tumors25) throughout the disease-course. The gene discussed is SMO; the disease is neoplasm.